Perampanel CAS 380917-97-5

Product Description:

Product Name: Perampanel CAS NO: 380917-97-5

Synonyms:

3-(2-Cyanophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one;

2-(6'-Oxo-1'-phenyl-1',6'-dihydro-[2,3'-bipyridin]-5'-yl)benzonitrile;

Benzonitrile, 2-(1',6'-dihydro-6'-oxo-1'-phenyl[2,3'-bipyridin]-5'-yl)-;

Chemical & Physical Properties:

Appearance: Crystalline solid

Assay :≥99.0%

Density: 1.31±0.1 g/cm3(Predicted)

Boiling Point: 619.1±55.0 ℃(Predicted)

Flash Point: 328.2±31.5℃

Vapour Pressure: 0.0±1.8 mmHg at 25℃

Index of Refraction: 1.706

Perampanel is the world's first non-competitive α -amino-3-hydroxy-5-methylisooxazol-4-propionic acid (AMPA) receptor antagonist developed by EISAIINC. It was approved by European EMA and American FDA in July and October 2012, respectively. It is used for adjunctive treatment of partial seizure epilepsy patients over 12 years of age with or without secondary major systemic seizures. On June 22, 2015, Eisai Announced that the U.S. Food and Drug Administration (FDA) has approved expanded indications for Pirampanet hydrate (Fycompa) as an adjunctive treatment for primary generalized tonic-clonic seizures in patients 12 years of age and older.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.